Leukopaks from Disease State and Healthy Donors
High-quality, high-volume, patient-centric, RUO apheresis products
from our diverse network of research-ready study participants
Leukopaks: One Donor, Billions of White Blood Cells
Large volumes of white blood cells can be separated by apheresis (leukapheresis) while plasma and red blood cells are returned to the donor. Research Use Only (RUO) leukapheresis products collected from the same donor provide a reliable and consistent source of up to 10 billion immune cells, including peripheral blood mononuclear cells (PBMCs), rare CD34+ cells, for biomarker, immunology, autologous, and allogeneic cell therapy research and product development.
Process Development
Cell & Gene Therapy
Assay Validation
Rare Cell Isolation
Leukopaks obtained from donors with confirmed disease closely resemble the autologous therapy that will be administered to patients, thereby providing more accurate data on immune cell subtypes and biomarkers.
Leukopaks from our network of 70,000+ donors
Diverse Donor Network
- 70,000 patient and healthy donors nationwide
- Confirmed disease diagnosis via medical record
- Medical histories
- Inclusion/Exclusion criteria
Comprehensive Donor Data
- Annotated medical records
- Study-specific questionnaires
- Infectious disease status
- HLA typing class 1 & 2
- Complete blood count (CBC)
- Demographics
Quality
- Adherence to standards and protocols ensures high cell viability & recovery
- Cryopreserved or fresh
- Same-day or next-day shipment
- Up to 10 billion (full) or 6 billion (half) immune cells, including PBMCs and CD34+ cells per leukopak
Recallable Donors
- Longitudinal studies with multiple time points
- Concurrent collection of additional sample types (e.g., urine, stool, skin tapes)
- Nationwide network of qualified apheresis clinics
Additional characterization & isolation capabilities, including:
Mononuclear cell isolation (PBMCs, T, B, and/or NK cells)
100+ additional CLIA-certified diagnostic tests
Percent abundance characterization of immune cell subtypes
Confirmed Disease State Leukopaks
Collected Under IRB Protocols
Trust Sanguine for Your Human Sample Research Needs:
Compliance & Quality Assured
Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval of all study protocols, specific study documentation, and study participant facing information. Both Advarra and WCG IRB are organized and operates in compliance with: FDA, OHRP, and International Conference on Harmonization (ICH).
Sanguine operates under an electronic informed consent process which executes 21 CFR part 11 compliant e-signatures, and Sanguine systems interacting with study participant information are HIPAA-compliant. Leukapheresis is conducted under an IRB-approved protocol at qualified blood clinic sites.
More than Biospecimen Procurement
Take advantage of our experienced and dedicated sample collection, logistics, processing, characterization, and storage capabilities to optimize and streamline your study design and mitigate unnecessary variability.
Publications using Sanguine PBMCs:
Learn More about Sanguine Leukopaks
To provide you with an accurate quote, please complete the short form.
Alternatively, to speak with someone directly, please contact:
Phone: 818-462-8290
Email: LearnMore@sanguinebio.com